Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience

Table 2 Previous and concomitant treatments at baseline

Treatment	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9	Case 10	Case 11
Previous treatment
NSAIDs
Diclofenac sodium	-	-	-	-	-	-	-	-	-	-	+
Naproxen	+	+	+	+	+	+	+	+	+	+	+
Celecoxib	-	-	-	+	-	-	-	-	-	-	-
Corticosteroid
Corticosteroid	+	+	+	+	+	+	+	+	+	+	+
Corticosteroid pulse	+	-	-	-	+	-	+	+	-	-	-
cDMARDs
Methotrexate	+	+	+	+	+	+	+	+	+	+	+
Cyclosporine A	-	-	-	-	-	-	-	+	-	-	-
Leflunomide	+	-	-	+	+	+	+	+	-	-	+
Thalidomide	+	+	-	+	-	+	+	+	+	-	+
Sulfasalazine	-	-	-	+	-	-	-	-	-	-	-
bDMARDs
Tocilizumab	+	+	+	+	+	+	+	+	+	+	+
Adalimumab	-	-	-	+	+	-	-	-	+	+	+
Etanercept	-	-	-	+	-	+	-	-	-	+	-
JAKi	-	-	-	-	-	-	+	-	-	-	+
Treatment at baseline
NSAIDs	+	+	+	+	-	+	-	+	+	+	+
Corticosteroid	+	-	-	+	+	-	-	+	-	-	-
cDMARDs
Methotrexate	+	+	+	-	+	+	-	+	+	+	+
Leflunomide	-	-	-	+	-	-	-	-	-	-	-
Thalidomide	-	-	-	-	-	-	-	-	+	-	+
Sulfasalazine	-	-	-	+	-	-	-	-	-	-	-
bDMARDs
Tocilizumab	-	+	+	+	-	+	+	+	-	-	+
Adalimumab	-	-	-	-	+	-	-	-	+	-	-
JAKi	-	-	-	-	-	-	-	-	-	-	+

NSAIDs Non-steroidal anti-inflammatory drugs, cDMARDs Conventional disease-modifying antirheumatic drugs, bDMARDs Biologic disease-modifying antirheumatic drugs, JAKi Janus kinase inhibitors

ISSN: 1546-0096